Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.

Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, Usmani SZ, Weisel K, Zonder JA, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson MA, Romanus D, Stull DM, Hungria V.

Future Oncol. 2019 Feb 28. doi: 10.2217/fon-2019-0013. [Epub ahead of print]

2.

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD Jr, Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R.

Br J Haematol. 2018 Mar;180(6):821-830. doi: 10.1111/bjh.15058. Epub 2018 Feb 13.

3.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
4.

Therapy sequencing strategies in multiple myeloma: who, what and why?

Costello C, Mikhael JR.

Future Oncol. 2018 Jan;14(2):95-99. doi: 10.2217/fon-2017-0493. Epub 2017 Dec 8. No abstract available.

5.

Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma.

Lazzari E, Mondala PK, Santos ND, Miller AC, Pineda G, Jiang Q, Leu H, Ali SA, Ganesan AP, Wu CN, Costello C, Minden M, Chiaramonte R, Stewart AK, Crews LA, Jamieson CHM.

Nat Commun. 2017 Dec 4;8(1):1922. doi: 10.1038/s41467-017-01890-w.

6.

Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies.

Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R.

JCO Precis Oncol. 2017 Jun;1. doi: 10.1200/PO.16.00004. Epub 2017 Apr 27.

7.

Social Media and Substance Use: What Should We Be Recommending to Teens and Their Parents?

Costello CR, Ramo DE.

J Adolesc Health. 2017 Jun;60(6):629-630. doi: 10.1016/j.jadohealth.2017.03.017. No abstract available.

PMID:
28532648
8.

A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis.

Goodman AM, Rust M, Costello C, Ball ED.

Oncology (Williston Park). 2017 Feb 15;31(2):122-4, 126-8. No abstract available.

9.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Feb;15(2):230-269.

PMID:
28188192
10.

An update on the role of daratumumab in the treatment of multiple myeloma.

Costello C.

Ther Adv Hematol. 2017 Jan;8(1):28-37. doi: 10.1177/2040620716677523. Epub 2016 Nov 24. Review.

11.

Adolescents and Social Media: Privacy, Brain Development, and the Law.

Costello CR, McNiel DE, Binder RL.

J Am Acad Psychiatry Law. 2016 Sep;44(3):313-21.

PMID:
27644864
12.

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ; Leukemia and Lymphoma Society Blood Cancer Research Partnership.

N Engl J Med. 2016 Jul 14;375(2):143-53. doi: 10.1056/NEJMoa1601202.

13.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2016 Apr;14(4):389-400.

14.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

15.

Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.

Holman PR, Costello C, deMagalhaes-Silverman M, Corringham S, Castro J, Ball ED.

Biol Blood Marrow Transplant. 2012 Feb;18(2):257-64. doi: 10.1016/j.bbmt.2011.06.011. Epub 2011 Jul 4.

16.

Supplemental Content

Loading ...
Support Center